Docosahexaenoic acid

PreclinicalSmall molecule

Docosahexaenoic acid is one of 47 small molecule programs targeting Retinitis Pigmentosa. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinitis PigmentosaActive, not recruiting

HypertensionActive, not recruiting

Retinitis PigmentosaPreclinical

Active, not recruiting

HypertensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

157 competitors in Hypertension

#DrugCompanyPhaseTrials

Baxfendy

AstraZeneca

Phase 3

3 2

Nitrostat

VViatris Specialty LLC

Phase 3

5 3

Alka-Seltzer

AAbbott

Phase 3

1 4

Minocycline /d

UUniversity of Florida

Phase 3

1 5

SGLT2

PProf. Dr. med. Ingo Eitel

Phase 3

1 6

Avastin

Roche

Preclinical

1 7

Winrevair

Alphagan

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 10

Nipride

EExela Pharma Sciences, LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Periodontitis1 trial

The Effects of DHA on Periodontitis

Completed·—·Phase 2·NCT01976806·55 enrolled

Amblyopia1 trial

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

Withdrawn·JJohns Hopkins University·Phase 1/2·NCT03402789

Sickle Cell Disease1 trial

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

Unknown status·MMicelle BioPharma Inc·Phase 2·NCT02973360·68 enrolled

Cystic Fibrosis1 trial

Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)

Completed·HHospices Civils de Lyon·Phase 2·NCT02690857·10 enrolled

Retinitis Pigmentosa1 trial

Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa

Completed·RRetina Foundation of the Southwest·N/A·NCT00004827·46 enrolled

7 more indications

Breast Cancer1 trial

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01849250·65 enrolled

Completed·VVA Office of Research and Development·Phase 1·NCT01563913·33 enrolled

Treatment1 trial

Evaluation of DHA for the Treatment of PSC

Completed·—·Phase 1·NCT00325013·10 enrolled

Cognitive impairment1 trial

Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients

Unknown status·FFudan University·Phase 1/2·NCT04242004·88 enrolled

Hypertension1 trial

Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health

Withdrawn·—·N/A·NCT02137408

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Docosahexaenoic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docosahexaenoic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docosahexaenoic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Micelle BioPharma Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMicelle BioPharma Inc

Docosahexaenoic acid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Periodontitis1 trial

Amblyopia1 trial

Sickle Cell Disease1 trial

Cystic Fibrosis1 trial

Retinitis Pigmentosa1 trial

Breast Cancer1 trial

Concussion1 trial

Cardiovascular1 trial

Parkinson's Disease1 trial

Treatment1 trial

Cognitive impairment1 trial

Hypertension1 trial

References

Drug Info

Quick Facts

Related News